What is Tiziana Life Sciences Ltd's (TLSA) StockRank?

MoatMap's StockRank for Tiziana Life Sciences Ltd (TLSA) is 1/100, with a Strong Sell signal. This is a composite score combining Quality (10), Value (32), and Momentum (23) factor ranks across MoatMap's 20,000+ stock universe.

Does Tiziana Life Sciences Ltd have an economic moat?

Tiziana Life Sciences Ltd (TLSA) has a Quality factor score of 10/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Tiziana Life Sciences Ltd a buy, hold, or sell?

MoatMap's current signal for Tiziana Life Sciences Ltd (TLSA) is Strong Sell, based on a StockRank of 1/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Tiziana Life Sciences Ltd in?

Tiziana Life Sciences Ltd (TLSA) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

TLSA

STRONG SELLREMOVE

Tiziana Life Sciences Ltd · Healthcare · United Kingdom · $186M · Avg Vol: $300K/d

StockRank

P/E (TTM)

—

ROE

-924.3%

D/E

8.8x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Tiziana Life Sciences is a pre-revenue biotechnology firm. It fails our Terry Smith and Warren Buffett criteria due to lack of cash flows, high binary clinical trial risk, and no established manufacturing or CDMO scale to benefit from the CDMO pricing power cycle.

COMPANY DESCRIPTION

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company focused on developing novel therapeutics for oncology, inflammatory diseases, and neurodegenerative disorders. The company's competitive moat is based on its innovative pipeline, particularly its orally administered antibody platform designed for improved drug delivery and efficacy. Tiziana operates as a niche biotech player, emphasizing novel mechanisms of action to address significant unmet medical needs.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-0.15	-0.17	-0.11	-0.16	—
Shares	102M	103M	111M	121M	+17.8%
Debt	365,000	247,000	106,000	456,000	7.7%
Equity	20M	6M	4M	52,000	-86.1%
Op CF	-20M	-16M	-2M	-13M	—
Inv CF	-4M	-1M	-71,000	3M	—
Fin CF	-55,000	40,000	5M	10M	—

PRICE (1M)-23.2%

SMA 50SMA 200

$1.16

RSI (14)

29.5

52W High

$2.60

From 52W High

0.4%

SCORE BREAKDOWN

Quality

ROIC

-6438.1%0.0

ROE

-924.3%0.7

GP/Assets

—N/A

Op. Margin

0.0%40.4

FCF/Assets

-47.6%5.0

Piotroski

—7.2

Int. Cover

-50.0x6.4

D/E Ratio

8.77x1.1

Current Ratio

0.76x4.7

Value

P/E (TTM)

—N/A

EV/EBITDA

-6.1x75.4

P/FCF

—N/A

P/B

14.3x7.1

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

45%18.3

RS 6M

-36%34.9

SMA 50/200

0.85x22.3

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-25%13.1

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$186M

P/E (Forward)

-5.5x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TLSA are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
TLSA	Tiziana Life Sciences Ltd(you)	$186M	1	STRONG SELL
4BB.L	4basebio PLC	$110M	5	STRONG SELL
BCYC	Bicycle Therapeutics plc	$326M	11	STRONG SELL
AVCT.L	Avacta Group Plc	$472M	14	STRONG SELL
IMM.L	ImmuPharma plc	$37M	1	STRONG SELL
HEMO.L	Hemogenyx Pharmaceuticals Plc	$63M	14	STRONG SELL
AUTL	Autolus Therapeutics plc	$471M	22	SELL
APTA.L	Aptamer Group PLC	$28M	3	STRONG SELL
SAR.L	Sareum Holdings plc	$47M	14	STRONG SELL
SCLP.L	Scancell Holdings plc	$333M	37	HOLD

Peer medians: ROE 1.2% · P/E 26.9x · Gross margin 51.4%

Tiziana Life Sciences Ltd (TLSA) — Stock Score Summary

Tiziana Life Sciences Ltd (TLSA) has a MoatMap StockRank of 1/100 based on Quality (10/100), Value (32/100), and Momentum (23/100) factor scores. The current signal is STRONG SELL. Tiziana Life Sciences is a pre-revenue biotechnology firm. It fails our Terry Smith and Warren Buffett criteria due to lack of cash flows, high binary clinical trial risk, and no established manufacturing or CDMO scale to benefit from the CDMO pricing power cycle.

Key Financial Metrics

Price	$1.16
Market Cap	$186M
P/E (Forward)	-5.51
Price/Book	14.29
Return on Equity	-924.3%
Return on Invested Capital	-6438.1%
Debt/Equity	876.92
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-5M

Tiziana Life Sciences Ltd operates in the Biotechnology industry, part of the Healthcare sector (United Kingdom).

Frequently Asked Questions

What is Tiziana Life Sciences Ltd’s (TLSA) StockRank?: MoatMap’s StockRank for Tiziana Life Sciences Ltd (TLSA) is 1/100, with a Strong Sell signal. It is a composite of Quality (10), Value (32), and Momentum (23) factor ranks across MoatMap’s 20,000+ stock universe.
Does Tiziana Life Sciences Ltd have an economic moat?: Tiziana Life Sciences Ltd (TLSA) has a Quality factor score of 10/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Tiziana Life Sciences Ltd a buy, hold, or sell?: MoatMap’s current signal for Tiziana Life Sciences Ltd (TLSA) is Strong Sell, based on a StockRank of 1/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Tiziana Life Sciences Ltd in?: Tiziana Life Sciences Ltd (TLSA) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).